Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Protocol 156-03-236: Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized With Worsening Congestive Heart Failure

Next Previous
X
Search
Trial Profile

Protocol 156-03-236: Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized With Worsening Congestive Heart Failure

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tolvaptan (Primary)
  • Indications Chronic heart failure; Heart failure
  • Focus Therapeutic Use
  • Acronyms EVEREST
  • Sponsors Otsuka Pharmaceutical Development & Commercialization

    • Most Recent Events

    • 01 Jul 2022 Results of a post-hoc analysis assessing rates of reversal of volume overload in patients hospitalized for acute HF over 10 months of median follow-up period published in the American Journal of Kidney Diseases
    • 23 Apr 2022 Using data (n=4133) of patients from this study was used to assess the the association between rates of in-hospital change in assessments of volume overload, including b-type natriuretic peptide (BNP), N-terminal pro b-type natriuretic peptide (NT-proBNP), as well as change in hemoconcentration, with risk of all-cause mortality and a composite outcome of cardiovascular mortality or heart failure hospitalization,published in the American Journal of Medicine
    • 28 May 2018 Chronic-heart-failure and Heart-failure are retained according to inclusion criteria.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top